Skip to NavigationSkip to content

oncolytic

Scientists use cold virus to treat bladder cancer

A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer cells, according to researchers from the University of Surrey.

In a study published in the journal Clinical Cancer Research, scientists investigated the safety and tolerability of exposure to the oncolytic (cancer killing) virus coxsackievirus (CVA21), a naturally occurring strain of the common cold virus.

World Vaccine & Immunotherapy Congress West Coast

World Vaccine and Immunotherapy Congress West Coast

Amgen bets on immunotherapy future

Published on 15/06/15 at 07:43am
Amgen image

When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future possibilities of new treatments for people with cancers.

Just days after Amgen’s oncolytic immunotherapy – T-VEC (talimogene laherparepvec) – hit the headlines, with noteworthy Phase III trial results in people with skin cancer, Lillie tells Pharmafile he feels that Amgen is set for big things in the field of immunotherapy.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches